EFFICACY AND SAFETY OF MIBEFRADIL IN HYPERTENSION VERSUS LOSARTAN

米贝拉地尔与氯沙坦治疗高血压的疗效和安全性

• 批准号: 6297156
• 负责人: ALAN B WEDER
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297156
• 关键词: calcium channel blockers; cardiovascular disorder chemotherapy; clinical research; dosage; drug screening /evaluation; human subject; human therapy evaluation; hypertension; losartan; vasodilators

The objective of the current study is to evaluate the differnce between mibefradil and losartan in the change of mean trough sitting diastolic blood pressure (SDBP) measurements after 8 weeks of active treatment. This study includes a 4-week placebo run-in period followed by an 8-week treatment period. During the first 4 weeks of the treatment period, the patients receive either mibefadil (50mg), or losartan(50mg). At week 4, patients responding to the study drug, mean trough SDBP<90mmHg, will continue on the same study drug at the same dose for four more weeks. Patients with mean trough SDBP>90mm Hg, will titrate up to a final dose of 100 mg once daily for the remaining 4 weeks through weeek 8.

当前研究的目的是评估Mibefradil和Losartan之间在平均槽静脉炎舒张压（SDBP）测量后进行8周进行主动治疗后的差异。这项研究包括一个为期4周的安慰剂磨合期，然后进行了为期8周的治疗期。 在治疗期的前4周内，患者接受Mibefadil（50mg）或Losartan（50mg）。 在第4周，对研究药物反应的患者平均SDBP <90mmHg，将继续使用同一剂量的同一研究药物持续四个星期。平均SDBP> 90mm Hg的患者将在剩下的4周内滴定每天100 mg的最终剂量，直到WEEEK 8。